UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The lancet oncology, ISSN 1470-2045, 2010, Volume 11, Issue 1, pp. 38 - 47
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Tomography, Spiral Computed | Liver Neoplasms - chemistry | Hepatectomy | Antibodies, Monoclonal, Humanized | Fluorouracil - therapeutic use | Austria | Leucovorin - adverse effects | Fluorouracil - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Female | Leucovorin - therapeutic use | Neoadjuvant Therapy | Retrospective Studies | Chemotherapy, Adjuvant | Cetuximab | Liver Neoplasms - secondary | Odds Ratio | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Camptothecin - therapeutic use | Liver Neoplasms - genetics | Risk Assessment | Liver Neoplasms - drug therapy | Linear Models | Liver Neoplasms - surgery | Proto-Oncogene Proteins - genetics | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Magnetic Resonance Imaging | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Aged | Mutation | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Germany | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 01/2012, Volume 366, Issue 1, pp. 44 - 53
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Biological and medical sciences | General aspects | Medical sciences | Tumors | Gene Expression | Microsatellite Instability | Colorectal Neoplasms - genetics | Epigenesis, Genetic | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Intercellular Signaling Peptides and Proteins - genetics | Male | Antineoplastic Agents - therapeutic use | Chemoradiotherapy | Transcription Factor AP-2 - metabolism | Colorectal Neoplasms - therapy | DNA Methylation | Drug Resistance, Neoplasm - genetics | Transcription Factor AP-2 - genetics | DNA - analysis | Colorectal Neoplasms - drug therapy | Cell Line, Tumor | Female | Aged | Mutation | Chemotherapy | Usage | Patient outcomes | Colorectal cancer | Research | Drug therapy | Drug resistance | Cancer | Transcription factors | Peptides | Pathogenesis | Cloning | Colorectal carcinoma | Chemoresistance | Biology | Metastasis | Microsatellite instability | Tumor cell lines | Gene expression | Patients | Metastases | Irinotecan | Oxaliplatin | Plasmids | DNA methylation | Genetic testing | Methylation | Deoxyribonucleic acid--DNA | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1355 - 1369
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Fluorouracil - therapeutic use | Neoplasm Metastasis | Leucovorin - adverse effects | Fluorouracil - adverse effects | Time Factors | Colorectal Neoplasms - drug therapy | Treatment Failure | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Leucovorin - therapeutic use | Maintenance Chemotherapy | Angiogenesis Inhibitors - adverse effects | Colorectal Neoplasms - mortality | Risk Factors | Kaplan-Meier Estimate | Capecitabine - therapeutic use | Disease Progression | Capecitabine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged | Colorectal Neoplasms - pathology | Drug Substitution | Organoplatinum Compounds - therapeutic use | Germany | Organoplatinum Compounds - adverse effects | Antimitotic agents | Cancer patients | Care and treatment | Chemotherapy | Colorectal cancer | Product development | Metastasis | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Journal of thoracic oncology, ISSN 1556-0864, 01/2015, Volume 10, Issue 1, pp. 156 - 163
ErbB family blocker | Non–small-cell lung cancer | Compassionate use program | Afatinib | Central nervous system metastasis | Non-small-cell lung cancer | Respiratory System | Oncology | Life Sciences & Biomedicine | Science & Technology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - enzymology | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Treatment Outcome | Brain Neoplasms - drug therapy | Disease Progression | Brain Neoplasms - secondary | Meningeal Neoplasms - drug therapy | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Meningeal Neoplasms - secondary
Journal Article
The Lancet (British edition), ISSN 0140-6736, 05/2019, Volume 393, Issue 10184, pp. 1948 - 1957
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Capecitabine - administration & dosage | Leucovorin - administration & dosage | Adenocarcinoma - pathology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Oxaliplatin - therapeutic use | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Fluorouracil - therapeutic use | Docetaxel - administration & dosage | Fluorouracil - administration & dosage | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Oxaliplatin - administration & dosage | Administration, Oral | Esophagogastric Junction - pathology | Treatment Outcome | Capecitabine - therapeutic use | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Digestive System Surgical Procedures | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Docetaxel - therapeutic use | Aged | Neoplasm Staging | Adenocarcinoma | Anthracyclines | Chemotherapy | Leucovorin | Product development | Esophageal cancer | Cancer | Intravenous administration | Control methods | Toxicity | Clinical trials | Oncology | Metastasis | Cancer therapies | Stomach cancer | Evidence-based medicine | Metastases | Confidence intervals | Infusion | Oxaliplatin | Surgery | Intravenous infusion | Epirubicin | Medical research | Survival | Patients | Cisplatin | Esophagus | Interactive systems | Medical prognosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 12/2001, Volume 19, Issue 23, pp. 4298 - 4304
Life Sciences & Biomedicine | Oncology | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Biological and medical sciences | Medical sciences | Tumors | Prognosis | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Male | RNA, Messenger - metabolism | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Retrospective Studies | DNA-Binding Proteins | Colorectal Neoplasms - mortality | Thymidylate Synthase - metabolism | California | DNA Primers | Reverse Transcriptase Polymerase Chain Reaction | Proteins - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Endonucleases | Survival Analysis | Aged | Colorectal Neoplasms - pathology | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 03/2008, Volume 26, Issue 9, pp. 1435 - 1442
Biological and medical sciences | Medical sciences | Tumors | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Aged, 80 and over | Adult | Female | Drug Administration Schedule | Kaplan-Meier Estimate | Esophagogastric Junction - pathology | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Aged | Esophageal Neoplasms - drug therapy | Germany | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 5/2019, Volume 68, Issue 5, pp. 799 - 812
Immunology | Medicine & Public Health | Active cancer immunotherapy | CV9201 | Non-small cell lung cancer | Oncology | Cancer Research | Clinical trial | mRNA | Immunomonitoring | Life Sciences & Biomedicine | Science & Technology | Squamous cell carcinoma | Care and treatment | Oncology, Experimental | Clinical trials | Development and progression | Lung cancer, Small cell | Research | B cells | Lung cancer, Non-small cell | T cells | Messenger RNA | Immunotherapy | Drug therapy | Cancer | Antigens | Lung cancer | Melanoma | Non-small cell lung carcinoma | Lymphocytes T | Survivin | Immunoglobulin D | Patients | Esophagus | Metastases | Lymphocytes B | Index Medicus
Journal Article
BMC cancer, ISSN 1471-2407, 07/2014, Volume 14, Issue 1, pp. 521 - 521
Irinotecan | Chemotherapy | Oxaliplatin | Phase I | Cetuximab | Metastatic colorectal cancer | 5-FU | Life Sciences & Biomedicine | Oncology | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Drug Administration Schedule | Humans | Liver Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Treatment Outcome | Maximum Tolerated Dose | Organoplatinum Compounds - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Liver Neoplasms - secondary | Organoplatinum Compounds - adverse effects | Camptothecin - analogs & derivatives | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 06/2009, Volume 27, Issue 17, pp. 2863 - 2873
Biological and medical sciences | Medical sciences | Tumors | Stomach Neoplasms - genetics | Pharmacogenetics - methods | Humans | Middle Aged | Male | Clinical Trials as Topic | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Fluorouracil - therapeutic use | Clinical Trials, Phase III as Topic | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Adenocarcinoma - genetics | Aged | Organoplatinum Compounds - therapeutic use | Index Medicus
Journal Article